USC.edu
Are You a Patient?

Mohamed Abou-el-Enein

Associate Professor of Medicine (Clinical Scholar), Pediatrics, Stem Cell Biology & Regenerative Medicine, Population & Public Health Sciences and Regulatory and Quality Sciences

Executive Director, Joint USC/CHLA Cell Therapy Program

Image of Mohamed Abou-el-Enein
Websites
Is this your profile? Click to edit
Email [email protected]
Orcid ID CTSI Profile

Publications

  • Molecular dynamics-guided design of sulfadiazine-based α-aminophosphonates as DNA gyrase inhibitors with enhanced binding stability and antibacterial activity. J Biomol Struct Dyn. 2026 Jun 02; 1.. View in PubMed
  • STROBE-causal machine learning for the human microbiome: systematic review on methodological innovations and validation frameworks. Front Microbiol. 2026; 17:1705116.. View in PubMed
  • Current state of CAR-T cell therapies for solid tumors. Med. 2026 May 08; 7(5):101028.. View in PubMed
  • Chitosan and dialdehyde starch as macromolecular platforms for sulfa azo dye/selenium nanocomposites: Synthesis, molecular modelling, and dual DNA gyrase-DHFR inhibition. Int J Biol Macromol. 2026 Feb; 346:150667.. View in PubMed
  • Molecular Therapy Advances: Building the bridge between discovery and cure. Mol Ther Methods Clin Dev. 2025 Dec 11; 33(4):101641.. View in PubMed
  • Revisiting the environmental resource curse in MENA: Do export diversification and renewable energy matter? J Environ Manage. 2025 Dec; 395:127749. Hassanein EA, Abouelenein MF , Ibrahiem DM, Esily RR . View in PubMed
  • Beyond just correlation: causal machine learning for the microbiome, from prediction to health policy with econometric tools. Front Microbiol. 2025; 16:1691503.. View in PubMed
  • Synthesis, Larvicidal Activity, and In Silico Mechanistic Insights of Novel Polyfunctionalized Pyridine Derivatives Against Culex pipiens L. Bioorg Chem. 2025 10; 165:108959.. View in PubMed
  • High-dimensional temporal mapping of CAR T cells reveals phenotypic and functional remodeling during manufacturing. Mol Ther. 2025 May 07; 33(5):2291-2309.. View in PubMed
  • Redefining quality in cell and gene therapies: Lessons from implementing electronic QMS in academic cGMP facility. Mol Ther. 2025 May 07; 33(5):2091-2103.. View in PubMed
  • The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell Malignancy. Blood Cancer Discov. 2024 Jul 01; 5(4):249-257.. View in PubMed
  • Integration of ζ-deficient CARs into the CD3ζ gene conveys potent cytotoxicity in T and NK cells. Blood. 2024 06 20; 143(25):2599-2611.. View in PubMed
  • Biomanufacturing in gene and cell therapy. Mol Ther Methods Clin Dev. 2024 Jun 13; 32(2):101261.. View in PubMed
  • Disseminating transformative gene and cell therapy research. Mol Ther Methods Clin Dev. 2024 Jun 13; 32(2):101246.. View in PubMed
  • Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood Adv. 2024 01 23; 8(2):484-496.. View in PubMed
  • Integration of ζ-deficient CARs into the CD3-zeta gene conveys potent cytotoxicity in T and NK cells. bioRxiv. 2023 Nov 14.. View in PubMed
  • Bringing base editing to the clinic: The next generation of genome editors. Mol Ther Methods Clin Dev. 2023 Dec 14; 31:101138.. View in PubMed
  • Advancing in vivo genome editing: B cell engineering via adenoviral delivery systems. Mol Ther. 2023 09 06; 31(9):2554-2556.. View in PubMed
  • CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products. Blood Adv. 2023 08 08; 7(15):4124-4134.. View in PubMed
  • Non-viral chimeric antigen receptor (CAR) T cells going viral. Immunooncol Technol. 2023 Jun; 18:100375.. View in PubMed
  • Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis. Cancer Gene Ther. 2023 06; 30(6):845-854.. View in PubMed
  • Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. JAMA Netw Open. 2022 12 01; 5(12):e2245956.. View in PubMed
  • Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023 01; 20(1):49-62.. View in PubMed
  • Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022 05; 19(5):342-355.. View in PubMed
  • Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD. Mol Ther. 2022 06 01; 30(6):2298-2314.. View in PubMed
  • Scalable Manufacturing of CAR T cells for Cancer Immunotherapy. Blood Cancer Discov. 2021 Sep; 2(5):408-422.. View in PubMed
  • Evidence generation and reproducibility in cell and gene therapy research: A call to action. Mol Ther Methods Clin Dev. 2021 Sep 10; 22:11-14.. View in PubMed
  • Unproven stem cell interventions: A global public health problem requiring global deliberation. Stem Cell Reports. 2021 06 08; 16(6):1435-1445.. View in PubMed
  • Detection of SARS-CoV-2-specific memory B cells to delineate long-term COVID-19 immunity. Allergy. 2021 08; 76(8):2595-2599.. View in PubMed
  • Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021 06; 18(6):379-393.. View in PubMed
  • Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial. BMJ. 2020 10 21; 371:m3734.. View in PubMed
  • COVID-19-Induced ARDS Is Associated with Decreased Frequency of Activated Memory/Effector T Cells Expressing CD11a+. Mol Ther. 2020 12 02; 28(12):2691-2702.. View in PubMed
  • Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies. Mol Ther. 2020 10 07; 28(10):2108-2110.. View in PubMed
  • Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals. Mol Ther Methods Clin Dev. 2020 Sep 11; 18:269-279.. View in PubMed
  • CAR T-cell product performance in haematological malignancies before and after marketing authorisation. Lancet Oncol. 2020 02; 21(2):e104-e116.. View in PubMed
  • Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy. Trends Biotechnol. 2020 10; 38(10):1099-1112.. View in PubMed
  • Cell and Gene Therapy Trials: Are We Facing an ‘Evidence Crisis’? EClinicalMedicine. 2019 Jan; 7:13-14. Abou-El-Enein M, Hey SP . . View in PubMed
  • Linking Scattered Stem Cell-Based Data to Advance Therapeutic Development. Trends Mol Med. 2019 01; 25(1):8-19.. View in PubMed
  • Telbivudine in chronic lymphocytic myocarditis and human parvovirus B19 transcriptional activity. ESC Heart Fail. 2018 10; 5(5):818-829.. View in PubMed
  • Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions. Stem Cells Transl Med. 2018 09; 7(9):676-685.. View in PubMed
  • The Human Genome Editing Race: Loosening Regulatory Standards for Commercial Advantage? Trends Biotechnol. 2019 02; 37(2):120-123. Cathomen T, Schüle S, Schüßler-Lenz M, Abou-El-Enein M . View in PubMed
  • Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence. Mol Ther. 2018 05 02; 26(5):1172-1176.. View in PubMed
  • Enhancing patient-level clinical data access to promote evidence-based practice and incentivize therapeutic innovation. Adv Drug Deliv Rev. 2018 Nov – Dec; 136.. View in PubMed
  • Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment. Cell Stem Cell. 2017 10 05; 21(4):427-430.. View in PubMed
  • Accelerating Patients’ Access to Advanced Therapies in the EU. Mol Ther Methods Clin Dev. 2017 Dec 15; 7:15-19.. View in PubMed
  • The path to successful commercialization of cell and gene therapies: empowering patient advocates. Cytotherapy. 2017 02; 19(2):293-298.. View in PubMed
  • Clinical Development of Cell Therapies: Setting the Stage for Academic Success. Clin Pharmacol Ther. 2017 Jan; 101(1):35-38.. View in PubMed
  • Overcoming Challenges Facing Advanced Therapies in the EU Market. Cell Stem Cell. 2016 09 01; 19(3):293-7.. View in PubMed
  • Strategies for Derisking Translational Processes for Biomedical Technologies. Trends Biotechnol. 2017 02; 35(2):100-108.. View in PubMed
  • Putting a price tag on novel autologous cellular therapies. Cytotherapy. 2016 08; 18(8):1056-1061.. View in PubMed
  • Deciphering the EU clinical trials regulation. Nat Biotechnol. 2016 Mar; 34(3):231-3.. View in PubMed
  • Gene therapy: a possible future standard for HIV care. Trends Biotechnol. 2015 Jul; 33(7):374-6.. View in PubMed
  • The business case for cell and gene therapies. Nat Biotechnol. 2014 Dec; 32(12):1192-3.. View in PubMed
  • A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV. Trends Mol Med. 2014 Nov; 20(11):632-42.. View in PubMed
  • Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs. Cytotherapy. 2013 Mar; 15(3):362-83.. View in PubMed

Similar People